ORCA Therapeutics Welcomes Renowned Oncologist, Prof. Bob Pinedo, MD, PhD, to its Scientific Advisory Board

[Amsterdam, 1 May 2024] – ORCA Therapeutics, a pioneering biopharmaceutical company dedicated to advancing cancer therapeutics, proudly announces the addition of Prof. Bob Pinedo, MD, PhD, to its Scientific Advisory Board (SAB).

Prof. Pinedo brings with him a wealth of experience and expertise, having served as the founder and Chairman of the Board of the VUmc Cancer Center Amsterdam, where research and patient care intersect seamlessly. With a distinguished career spanning decades, Prof. Pinedo has made significant contributions to the field of medical oncology, exemplified by his extensive publication record and numerous international awards.

“Prof. Pinedo’s dedication to advancing oncological research and patient care aligns perfectly with ORCA’s mission,” said CEO Wenliang Dong. “His insights and guidance will be invaluable as we continue to push the boundaries of cancer therapeutics and bring hope to patients worldwide.”

Throughout his illustrious career, Prof. Pinedo has received numerous accolades, including the prestigious Dr. Josef Steiner Cancer Research Foundation Award, the NOW Spinoza Prize, and the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology. He has also been honored by H.M. Queen Beatrix of the Netherlands as a Knight in the Order of the Netherlands Lion.

As a Visiting Professor at Johns Hopkins University and Technical University Twente, Prof. Pinedo continues to shape the future of oncology through his mentorship and collaboration. He also serves as Chairman of the Board of the Caribbean Prevention Center in Curaçao and as Chairman of the International Advisory Board of the Vrije University Imaging Center.

Prof. Pinedo’s appointment to ORCA’s SAB further solidifies the company’s commitment to excellence in cancer research and therapeutic development. His unparalleled expertise will guide ORCA as it advances its groundbreaking therapies and strives to make a meaningful impact in the fight against cancer.

For media inquiries or further information, please contact Wenliang Dong at wen.dong@orca-therapeutics.com.

About ORCA Therapeutics BV:
ORCA is a clinical stage biopharmaceutical company dedicated to developing oncolytic immunotherapies for cancer treatment. With a focus on innovative gene therapies, ORCA Therapeutics is committed to improving patient outcomes and addressing unmet medical needs.
Learn more at www.orca-therapeutics.com